Amperozide

DB08927ExperimentalSmall molecule

Amperozide is a diphenylbutylpiperazine atypical antipsychotic which antagonizes 5-HT2A receptors. It inhibits dopamine release and alters the firing of dopaminergic neurons. Investigations regarding the use of the agent revolved primarily... Investigations regarding the use of the agent revolved primarily around its capability for treating schizophrenia in humans even though the drug was ultimately never clinically adopted for this indication.

Formula / weight: C₂₃H₂₉F₂N₃O · 401.4927 g/mol (avg)

Resolves to

Compound

UNII0M2W3TAG39CAS75558-90-6ChEMBLCHEMBL1079935ChEBI92913PubChem73333

Structure

InChIKeyNNAIYOXJNVGUOM-UHFFFAOYSA-NSMILES[H]N(CC)C(=O)N1CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1

Targets

P28223HTR2A

What you can answer from here — as of February 21, 2021

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

733Drug interactionsStructured to mechanism, not free text

10+ReferencesStructured and connected to the statements they support

Which drugs share a target with Amperozide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account